UTHR - United Therapeutics Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Silver Spring,
United States
Type: Equity
UTHR price evolution
UTHR
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1207.7 | $1107.7 | $1067.3 | $1163.5 |
| Short term investments | $1786.4 | $1767.8 | $1611.7 | $1699.9 |
| Net receivables | $278.9 | $258.6 | $272.7 | $134.5 |
| Inventory | $111.8 | $104.3 | $103.3 | $102.5 |
| Total current assets | $3551 | $3458.9 | $3213.4 | $3193 |
| Long term investments | $1909.8 | $2060.8 | $2023.6 | $1765.6 |
| Property, plant & equipment | $1045.4 | $992.2 | $938.9 | $896.5 |
| Goodwill & intangible assets | $114.2 | $44.4 | $44.5 | $44.5 |
| Total noncurrent assets | $3616 | $3564.7 | $3467.9 | $3153 |
| Total investments | $3696.2 | $3828.6 | $3635.3 | $3465.5 |
| Total assets | $7167 | $7023.6 | $6681.3 | $6346 |
| Current liabilities | ||||
| Accounts payable | $298 | $333.4 | $292 | $239.7 |
| Deferred revenue | ||||
| Short long term debt | $400 | $300 | ||
| Total current liabilities | $804.4 | $744.1 | $370.3 | $324.6 |
| Long term debt | $300 | $500 | $800 | $800 |
| Total noncurrent liabilities | $377.8 | $567.4 | $900 | $898.2 |
| Total debt | $700 | $800 | $800 | $800 |
| Total liabilities | $1182.2 | $1311.5 | $1270.3 | $1222.8 |
| Shareholders' equity | ||||
| Retained earnings | $6027.1 | $5810 | $5542.4 | $5283.2 |
| Other shareholder equity | -$12.8 | -$43.7 | -$50.6 | -$38.8 |
| Total shareholder equity | $5984.8 | $5712.1 | $5411 | $5123.2 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1207.7 | $961.2 | $894.8 | $738.7 |
| Short term investments | $1786.4 | $1877.5 | $1035.9 | $1096.3 |
| Net receivables | $278.9 | $220.4 | $198.7 | $157.4 |
| Inventory | $111.8 | $102 | $93.8 | $86.5 |
| Total current assets | $3551 | $3380.3 | $2323.6 | $2167.2 |
| Long term investments | $1909.8 | $1316.2 | $1649.9 | $1149.6 |
| Property, plant & equipment | $1045.4 | $861.5 | $780.9 | $731.6 |
| Goodwill & intangible assets | $114.2 | $44.5 | $44.6 | $158.1 |
| Total noncurrent assets | $3616 | $2664.2 | $2845.5 | $2447.8 |
| Total investments | $3696.2 | $3193.7 | $2685.8 | $2245.9 |
| Total assets | $7167 | $6044.5 | $5169.1 | $4615 |
| Current liabilities | ||||
| Accounts payable | $298 | $4.1 | $174.6 | $187 |
| Deferred revenue | ||||
| Short long term debt | $400 | |||
| Total current liabilities | $804.4 | $343.2 | $305.4 | $323.3 |
| Long term debt | $300 | $800 | $800 | $800 |
| Total noncurrent liabilities | $377.8 | $904.6 | $904.8 | $896.5 |
| Total debt | $700 | $800 | $800 | $800 |
| Total liabilities | $1182.2 | $1247.8 | $1210.2 | $1219.8 |
| Shareholders' equity | ||||
| Retained earnings | $6027.1 | $5042.3 | $4315 | $3839.2 |
| Other shareholder equity | -$12.8 | $0.9 | -$23 | -$14.2 |
| Total shareholder equity | $5984.8 | $4796.7 | $3958.9 | $3395.2 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $614.7 | $609.4 | $596.5 | $506.9 |
| Cost of revenue | $71 | $70.1 | $64.1 | $52.3 |
| Gross Profit | $543.7 | $539.3 | $532.4 | $454.6 |
| Operating activities | ||||
| Research & development | $151.4 | $84.7 | $89 | $82.9 |
| Selling, general & administrative | $132.2 | $127.6 | $130 | $87.3 |
| Total operating expenses | $283.6 | $212.3 | $219 | $170.2 |
| Operating income | $260.1 | $327 | $313.4 | $284.4 |
| Income from continuing operations | ||||
| EBIT | $310.5 | $367.4 | $350 | $305.7 |
| Income tax expense | $78.3 | $84.2 | $76 | $51 |
| Interest expense | $15.1 | $15.6 | $14.8 | $13.8 |
| Net income | ||||
| Net income | $217.1 | $267.6 | $259.2 | $240.9 |
| Income (for common shares) | $217.1 | $267.6 | $259.2 | $240.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2327.5 | $1936.3 | $1685.5 | $1483.3 |
| Cost of revenue | $257.5 | $151.6 | $122.5 | $108.1 |
| Gross Profit | $2070 | $1784.7 | $1563 | $1375.2 |
| Operating activities | ||||
| Research & development | $408 | $322.9 | $540.1 | $357.7 |
| Selling, general & administrative | $477.1 | $482.1 | $467 | $423.9 |
| Total operating expenses | $885.1 | $805 | $1007.1 | $781.6 |
| Operating income | $1184.9 | $979.7 | $555.9 | $593.6 |
| Income from continuing operations | ||||
| EBIT | $1333.6 | $983 | $612.5 | $662.4 |
| Income tax expense | $289.5 | $223.3 | $118.1 | $124.1 |
| Interest expense | $59.3 | $32.4 | $18.6 | $23.5 |
| Net income | ||||
| Net income | $984.8 | $727.3 | $475.8 | $514.8 |
| Income (for common shares) | $984.8 | $727.3 | $475.8 | $514.8 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $217.1 | $267.6 | $259.2 | $240.9 |
| Operating activities | ||||
| Depreciation | $13.7 | $13.3 | $12.9 | $13.3 |
| Business acquisitions & disposals | -$89.2 | |||
| Stock-based compensation | $16.6 | $21.1 | $13.8 | -$12.4 |
| Total cash flows from operations | $150.7 | $346.2 | $106.3 | $374.8 |
| Investing activities | ||||
| Capital expenditures | -$78.7 | -$65.7 | -$44.7 | -$41.3 |
| Investments | $210 | -$247.7 | -$182.5 | -$179.8 |
| Total cash flows from investing | $42.1 | -$313.4 | -$227.2 | -$221.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.3 | $4.6 | $24.7 | $61.4 |
| Net borrowings | -$100 | -$2.7 | ||
| Total cash flows from financing | -$92.8 | $7.6 | $24.7 | $48.6 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $100 | $40.4 | -$96.2 | $202.3 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $984.8 | $727.3 | $475.8 | $514.8 |
| Operating activities | ||||
| Depreciation | $53.2 | $51.3 | $49.9 | $49.9 |
| Business acquisitions & disposals | -$89.2 | $8.6 | ||
| Stock-based compensation | $39.1 | $106.8 | $138.5 | $163.8 |
| Total cash flows from operations | $978 | $802.5 | $598.2 | $755.7 |
| Investing activities | ||||
| Capital expenditures | -$230.4 | -$138.8 | -$120.8 | -$56.9 |
| Investments | -$400 | -$681.3 | -$366.1 | -$681.6 |
| Total cash flows from investing | -$719.6 | -$811.5 | -$486.9 | -$738.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $98 | $88.4 | $55.6 | $38.5 |
| Net borrowings | -$102.7 | -$7.5 | -$51.7 | |
| Total cash flows from financing | -$11.9 | $75.4 | $44.8 | -$16.9 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $246.5 | $66.4 | $156.1 | $0.3 |
News
Fundamentals
| Market cap | $11.10B |
|---|---|
| Enterprise value | $10.59B |
| Shares outstanding | 47.04M |
| Revenue | $2.33B |
|---|---|
| EBITDA | $1.39B |
| EBIT | $1.33B |
| Net Income | $984.80M |
| Revenue Q/Q | 25.07% |
| Revenue Y/Y | 20.20% |
| P/E ratio | 11.27 |
|---|---|
| EV/Sales | 4.55 |
| EV/EBITDA | 7.64 |
| EV/EBIT | 7.94 |
| P/S ratio | 4.77 |
| P/B ratio | 1.85 |
| Book/Share | 127.50 |
| Cash/Share | 25.67 |
| EPS | $20.94 |
|---|---|
| ROA | 14.47% |
| ROE | 17.72% |
| Debt/Equity | 0.20 |
|---|---|
| Net debt/EBITDA | -0.02 |
| Current ratio | 4.41 |
| Quick ratio | 4.28 |